Onconetix Inc (ONCO)

Jun 16, 2025, 8:22 AM EDT - 11 days ago

Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel

Jun 11, 2025, 11:30 AM EDT - 16 days ago

Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders

May 22, 2025, 4:50 PM EDT - 5 weeks ago

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

May 22, 2025, 10:00 AM EDT - 5 weeks ago

Onco-Innovations Uplists to Cboe Canada

Mar 24, 2025, 8:45 AM EDT - 3 months ago

Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort

Mar 19, 2025, 8:00 AM EDT - 3 months ago

Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress

Dec 12, 2024, 5:00 PM EST - 7 months ago

Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing

Oct 8, 2024, 5:00 AM EDT - 9 months ago

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

ENTO OCS VRNA

Oct 3, 2024, 4:45 PM EDT - 9 months ago

Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Oct 3, 2024, 9:05 AM EDT - 9 months ago

Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Sep 27, 2024, 2:41 PM EDT - 9 months ago

Crude Oil Rises; Onconetix Shares Spike Higher

Sep 20, 2024, 11:45 AM EDT - 10 months ago

Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders

Jul 15, 2024, 6:00 AM EDT - 1 year ago

Onconetix Announces Closing of Warrant Exercise for $1.11 Million Gross Proceeds

Jul 11, 2024, 8:17 AM EDT - 1 year ago

Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds

Feb 13, 2024, 6:00 AM EST - 1 year ago

Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors

Dec 19, 2023, 7:00 AM EST - 1 year ago

Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders

Dec 18, 2023, 7:00 AM EST - 1 year ago

Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™

Nov 2, 2023, 7:00 AM EDT - 1 year ago

Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company

Nov 1, 2023, 7:00 AM EDT - 1 year ago

Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1)

Oct 30, 2023, 7:00 AM EDT - 1 year ago

Blue Water Biotech Issues Letter to Shareholders

Oct 10, 2023, 9:00 AM EDT - 1 year ago

Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO

Aug 28, 2023, 4:30 PM EDT - 1 year ago

Blue Water Biotech, Inc. Announces Notification From Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Aug 3, 2023, 1:02 PM EDT - 2 years ago

Blue Water Biotech Announces Closing of Warrant Exercise and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds

Aug 1, 2023, 8:00 AM EDT - 2 years ago

Blue Water Biotech Announces Exercise of Warrants and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds

Jul 31, 2023, 9:00 AM EDT - 2 years ago

Blue Water Biotech and Knipper Health Join Forces to Distribute Samples for ENTADFI® and ZONTIVITY® to Physicians

Jul 25, 2023, 9:00 AM EDT - 2 years ago

Blue Water Biotech Teams with UpScriptHealth to Launch Telemedicine Platform for Benign Prostatic Hyperplasia Asset, ENTADFI®

Jul 17, 2023, 9:00 AM EDT - 2 years ago

Blue Water Biotech Issues CEO Shareholder Letter Providing Update on Commercial Launch Activities

Jul 11, 2023, 9:00 AM EDT - 2 years ago

Blue Water Biotech Teams with Advantage Point Solutions to Provide Healthcare Payer Coverage Support

Jul 6, 2023, 5:05 PM EDT - 2 years ago

Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for its FDA Approved Products

Jul 6, 2023, 7:30 AM EDT - 2 years ago

Blue Water Biotech Teams with BFW Advertising to Market and Advertise Commercial Product Portfolio

Jun 28, 2023, 7:55 AM EDT - 2 years ago

Blue Water Biotech Announces Preclinical Data Supporting Immunogenicity of Novel Monkeypox Vaccine Utilizing Norovirus Virus-Like Particle Platform

Jun 21, 2023, 7:30 AM EDT - 2 years ago

Blue Water Biotech Collaborates with IQVIA to Build Medical Sales Representative Team to Market Commercial Product Portfolio

Jun 14, 2023, 7:30 AM EDT - 2 years ago

Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas

May 12, 2023, 6:32 PM EDT - 2 years ago

Blue Water Biotech Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 10, 2023, 12:15 PM EDT - 2 years ago

Blue Water Biotech to Present Corporate Overview and ENTADFI® Launch Plan at the JMP Securities Life Sciences Conference in New York, NY

Apr 26, 2023, 3:44 PM EDT - 2 years ago

Blue Water Biotech Appoints Board-Certified Urologist Jay Newmark, M.D., MBA as Chief Medical Officer

Apr 25, 2023, 8:00 AM EDT - 2 years ago

Blue Water Biotech to Participate in the American Urological Association Annual Meeting 2023 to Promote Benign Prostatic Hyperplasia Treatment ENTADFI®

Apr 24, 2023, 8:00 AM EDT - 2 years ago

Blue Water Vaccines Announces Corporate Name Change to Blue Water Biotech in Connection with Transition into Commercial-Stage Biotechnology Company

Apr 20, 2023, 7:30 AM EDT - 2 years ago

Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset

Apr 12, 2023, 8:30 AM EDT - 2 years ago

Blue Water Vaccines Announces Signing of Sponsored Research Agreement with The University of Texas Health Science Center at San Antonio to Initiate Non-Human Primate Study for Live Attenuated, Orally Delivered Chlamydia Vaccine

Mar 9, 2023, 8:30 AM EST - 2 years ago

Blue Water Vaccines Reports Year 2022 Financial Results and Recent Business Highlights

Feb 6, 2023, 10:15 AM EST - 2 years ago

Blue Water Vaccines Appoints Seasoned Commercial Operations Leader Frank Jaeger as Senior Vice President of Marketing and Business Development

Feb 1, 2023, 9:15 AM EST - 2 years ago

Blue Water Vaccines Announces Partnership with AbVacc for Joint Development of Novel Monkeypox and Marburg Vaccine Candidates

Jan 17, 2023, 8:30 AM EST - 2 years ago

Blue Water Vaccines Announces Appointment of Seasoned Public Market and Private Equity Investment Leader Timothy Ramdeen to Board of Directors

Jan 9, 2023, 8:30 AM EST - 2 years ago

Blue Water Vaccines to Present at Biotech Showcase 2023 During the 41st Annual J.P. Morgan Healthcare Conference Week in San Francisco

Dec 12, 2022, 8:30 AM EST - 2 years ago

Blue Water Vaccines Announces Institutional Research Coverage by Two Notable Healthcare-Focused Wall Street Banks, Receives “Buy” Rating From Both

Dec 6, 2022, 8:30 AM EST - 2 years ago

Blue Water Vaccines Organizes Key Opinion Leader Event to Discuss Unmet Need for Acute Otitis Media and Pneumonia Vaccine and Its Streptococcus pneumoniae Vaccine Candidate

Dec 1, 2022, 8:30 AM EST - 2 years ago

Blue Water Vaccines to Present Update on Novel, Live Attenuated, Intranasally Delivered Streptococcus pneumoniae Vaccine to Prevent Acute Otitis Media, Pneumococcal Pneumonia, and Invasive Pneumococcal Disease at the World Vaccine & Immunotherapy Congress

Nov 10, 2022, 8:47 AM EST - 2 years ago

Blue Water Vaccines Reports Third Quarter 2022 Financial Results and Recent Business Highlights; Announces 5 Million Share Repurchase Program

Oct 11, 2022, 9:15 AM EDT - 2 years ago

Blue Water Vaccines Announces Plans to Evaluate Efficacy of Streptococcus pneumoniae Vaccine Candidate Against Pneumococcal Pneumonia at the World Vaccine Congress in Barcelona